Artixio

Global Pharma Regulatory Affairs Services

Biologics Regulatory Affairs Consultant in India

Your Trusted Partner for Biologics Regulatory Affairs Consulting in India. Expert Support for Biologics Registration, Compliance, and Lifecycle Management in India.

Regulatory Affairs Consulting for Biologics in India

Artixio provides regulatory affairs consulting services for biologics companies looking to operate in the Indian market. We support the registration and lifecycle management of biosimilars, monoclonal antibodies, vaccines, and advanced therapies like cell and gene products.

Our team works closely with clients to prepare regulatory submissions, manage communication with CDSCO, and handle updates across development and post-approval phases. With strong familiarity with India’s biologics guidelines, we help companies stay aligned with local expectations and avoid delays.

Biologics Regulatory Authorities in India:

Regulatory Body Role
Central Drugs Standard Control Organization (CDSCO) Main regulatory authority responsible for approval of biologics, including clinical trials, import, manufacture, and marketing.
Drug Controller General of India (DCGI) Head of CDSCO; grants approval for biologics, biosimilars, vaccines, and oversees regulatory decisions.
Review Committee on Genetic Manipulation (RCGM) Reviews preclinical data and grants approval for research involving GMOs and biologics at the research stage.

Why Artixio for Biologics Regulatory Affairs in India

Experience with CDSCO, RCGM, and GEAC regulatory authorities
30+ years of combined experience in biologics regulatory affairs
Skilled in managing local queries, clarifications, and regulatory meetings with Indian authorities
Expertise in dossier preparation, technical justifications, comparability data, and post-approval variations
Guidance on preclinical/clinical trial applications for novel biologics and GMO-based products
Support for global companies entering India with end-to-end biologics registration services

FAQs

What types of biologics does Artixio support for regulatory approval in India?

We support a wide range of biologics including biosimilars, monoclonal antibodies (mAbs), therapeutic proteins, gene and cell therapies, vaccines, and recombinant products for CDSCO, RCGM, and GEAC submissions.

Yes. Depending on the product type, you may need approvals from CDSCO (for market authorization), RCGM (for research involving GMOs), and GEAC (for environmental clearance, especially for recombinant biologics).

Timelines vary based on product type and data availability. Typically, approval may take 6–12 months for biosimilars with prior global approval. For novel biologics or gene therapies, timelines may be longer due to preclinical and clinical requirements.

Still Have Questions ?

Get expert answers tailored to your needs.

Specialized Regulatory Affairs
Services Across Multiple Industries

Pharmaceuticals

MedTech

Cosmetics

Nutrition

Biologics

Veterinary

Expert Regulatory Services To Streamline Compliance

Regulatory Intelligence & Strategy
Medical & Technical Writing
Publishing & Submission
Product Registration
Investigation New Drug Application (IND)
New Drug Application (NDA)
Post Approval Lifecycle Maintenance
Artwork and Label Review
Ad Promo Review

Regulatory Affairs Across Multiple Countries

India

Singapore

Mexico

Brazil

Vietnam

Malaysia

Argentina

Colombia

Taiwan

China

China

Thailand

Indonesia

Philippines

USA

Japan

Qatar

South Korea

Insights from Artixio - Tips & Articles

Orphan Drug Designation in South Korea (MFDS)

Orphan Drug Designation in

Orphan Drug Designation (ODD) is regulated by Ministry of Food and Drug Safety (MFDS)...

November 4, 2025
Prioritizing Genes from Publicly Available GWAS Summary Stats Using AI

Prioritizing Genes from Publicly

Artixio has developed an artificial intelligence based solution generating a list of prioritized genes...

October 13, 2025
CDSCO Simplifies Subsequent Importer Process for Medical Devices & IVDs

CDSCO Simplifies Subsequent Importer

India’s regulatory authority, the Central Drugs Standard Control Organization (CDSCO), has published an important...

October 3, 2025